Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02393157 · ClinicalTrials.gov registry record · Phase 2

Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

A Phase 2 study of Diffuse Large B Cell Lymphoma and Non-Hodgkin Lymphoma, sponsored by New York Medical College.

Recruiting
Registry status
Phase 2
Development phase
25
Enrollment target
1
Study location

NCT02393157 is a Phase 2 study of Diffuse Large B Cell Lymphoma and Non-Hodgkin Lymphoma that is actively recruiting participants, run by New York Medical College. The registered enrollment target is 25 participants, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02393157, a Phase 2 study of Diffuse Large B Cell Lymphoma and Non-Hodgkin Lymphoma, is actively recruiting participants, sponsored by New York Medical College.

RECRUITING
Registry status
Phase 2
Development phase
25 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine the safety of administering obinutuzumab as a single agent alone and in combination with ifosfamide, carboplatin, and etoposide (ICE) chemotherapy and determine the response rate of this treatment for children, adolescents and young adults (CAYA) with relapsed CD20 positive B-cell Non-Hodgkin Lymphoma (B-NHL).

Conditions Studied

Diffuse Large B Cell Lymphoma Non-Hodgkin Lymphoma Burkitt Lymphoma Primary Mediastinal B-cell Lymphoma CD20+ Lymphoblastic Lymphoma Follicular Lymphoma, Grade III

Interventions

  • DRUG Obinutuzumab
  • DRUG Carboplatin
  • DRUG Etoposide
  • DRUG Ifosfamide
  • DRUG Liposomal ARA-C

Study Locations (1)

New York

  • New York Medical College - Valhalla

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2015-08-21
Est. Completion 2027-12
Phase Phase 2

Sponsor

New York Medical College

47 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02393157

The ClinicalTrials.gov registry entry for NCT02393157 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (89% lower). The listed sponsor is New York Medical College, which has 47 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Diffuse Large B Cell Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Obinutuzumab is the first listed.

NCT02393157 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT02393157 about?

NCT02393157 is a clinical study titled "Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL". The purpose of this study is to determine the safety of administering obinutuzumab as a single agent alone and in combination with ifosfamide, carboplatin, and etoposide (ICE) chemotherapy and determine the response rate of this treatment for children, adolescents and young adults (CAYA) with relaps...

What is the current status of trial NCT02393157?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2015-08-21. Estimated completion is 2027-12.

What conditions does trial NCT02393157 study?

This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma, Non-Hodgkin Lymphoma, Burkitt Lymphoma, Primary Mediastinal B-cell Lymphoma, CD20+ Lymphoblastic Lymphoma.

What interventions are being tested in trial NCT02393157?

The interventions under investigation include: Obinutuzumab (DRUG), Carboplatin (DRUG), Etoposide (DRUG), Ifosfamide (DRUG), Liposomal ARA-C (DRUG).

Who is sponsoring clinical trial NCT02393157?

This trial is sponsored by New York Medical College, which has 47 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02393157 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diffuse Large B Cell Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Diffuse Large B Cell Lymphoma

All registered trials for this condition

Non-Hodgkin Lymphoma

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.